4 results match your criteria: "University Hospital H Mondor[Affiliation]"
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Haematologica
December 2022
Department of Hematology, Dijon-Bourgogne University Hospital, Dijon; INSERM unit 1231, University of Burgundy Franche-Comté, France.
Article Synopsis
- Stage IIB Hodgkin lymphoma (HL) patients with certain risk factors have a poor prognosis and are treated either as limited or advanced stage, with differing clinical trials comparing these treatment approaches.
- A study involving 148 patients showed that baseline total metabolic tumor volume (TMTV) and responses after two cycles of chemotherapy significantly influenced progression-free survival rates, with a median follow-up of 4.1 years showing PFS rates around 88%.
- The findings suggest that both upfront ABVD plus radiation therapy and upfront escBEACOPP without radiotherapy yield similar outcomes in these high-risk patients, while TMTV can effectively stratify their risk at baseline.
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
J Clin Oncol
April 2022
Department of Hematology, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France.
Purpose: The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) provides similar progression-free survival (PFS) and overall survival (OS) and reduces early toxicity compared with a nonmonitored standard treatment. Here, we report, with a prolonged follow-up, the final study results.
View Article and Find Full Text PDFPET-guided, BEACOPP therapy in advanced Hodgkin lymphoma - Authors' reply.
Lancet Oncol
April 2019
LYSA Imaging, University Hospital H Mondor, Creteil, France.
Amyl nitrite inhalation, a "volatile" anemia.
Am J Hematol
June 2016
Hematology Laboratory, University Hospital of Nancy, Nancy, France.